Elevance Health, Inc. (NYSE:ELV) Shares Sold by Mariner LLC

Mariner LLC decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 13.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,706 shares of the company’s stock after selling 11,891 shares during the period. Mariner LLC’s holdings in Elevance Health were worth $27,190,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ELV. Virtu Financial LLC acquired a new position in Elevance Health during the third quarter worth about $2,828,000. Te Ahumairangi Investment Management Ltd boosted its position in shares of Elevance Health by 39.6% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 10,508 shares of the company’s stock valued at $5,433,000 after purchasing an additional 2,983 shares in the last quarter. Tudor Financial Inc. acquired a new position in shares of Elevance Health in the 3rd quarter worth approximately $235,000. Anchor Investment Management LLC raised its holdings in shares of Elevance Health by 22.9% in the 3rd quarter. Anchor Investment Management LLC now owns 6,098 shares of the company’s stock worth $3,171,000 after purchasing an additional 1,135 shares in the last quarter. Finally, World Investment Advisors LLC bought a new stake in Elevance Health during the third quarter worth approximately $8,855,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CAO Ronald W. Penczek sold 443 shares of Elevance Health stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the transaction, the executive vice president now directly owns 10,116 shares in the company, valued at $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Elevance Health Trading Down 0.8 %

NYSE ELV opened at $437.83 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The firm’s fifty day simple moving average is $414.67 and its 200-day simple moving average is $412.17. The company has a market capitalization of $99.12 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 1.18 and a beta of 0.77.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th were paid a $1.71 dividend. The ex-dividend date of this dividend was Monday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a yield of 1.56%. Elevance Health’s payout ratio is 26.71%.

Analyst Ratings Changes

Several research firms have issued reports on ELV. Mizuho upped their price target on Elevance Health from $455.00 to $505.00 and gave the company an “outperform” rating in a report on Wednesday, April 9th. Robert W. Baird reiterated a “neutral” rating and issued a $529.00 price target (down previously from $625.00) on shares of Elevance Health in a research report on Tuesday. Argus raised Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price target on the stock in a research note on Monday, March 17th. Wells Fargo & Company reduced their price objective on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Finally, StockNews.com raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $514.41.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.